WestVac Biopharma Co., Ltd.
13
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
15.4%
2 terminated/withdrawn out of 13 trials
75.0%
-11.5% vs industry average
23%
3 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Role: lead
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
Role: lead
Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents
Role: lead
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
Role: lead
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)
Role: lead
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
Role: lead
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
Role: lead
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
Role: lead
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Role: lead
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
Role: lead
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
Role: lead
Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
Role: lead
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
Role: lead
All 13 trials loaded